Details for Patent: 7,960,424

Analysis of Patent 7,960,424: Scope, Claims, and Patent Landscape

What is the scope of Patent 7,960,424?

United States Patent 7,960,424 covers a specific chemical compound used in pharmaceutical formulations. Its scope includes the compound itself, methods of synthesis, and therapeutic uses. The patent aims to protect both the molecule and its application, with claims extending to various formulations and treatment methods.

What are the key claims of Patent 7,960,424?

The claims define the boundaries of patent protection. Key elements include:

• Chemical Structure: The patent claims a novel compound characterized by a specific chemical scaffold. The structure is specified through detailed chemical formulas, including substituents and stereochemistry.

• Method of Synthesis: Claims encompass the synthetic route to produce the compound, detailing reagents, conditions, and intermediate steps.

• Therapeutic Use: The patent claims the use of the compound in treating particular diseases, notably neurodegenerative disorders. Specific indications include Alzheimer’s disease, Parkinson’s disease, or related conditions.

• Formulations: Claims extend to pharmaceutical compositions comprising the compound, with particular excipients or delivery mechanisms.

• Dosage Methods: The patent covers methods involving specific dosing regimens and administration routes (oral, injectable).

• Claim Scope Variability: The claims are structured in multiple dependent and independent claims, with broad and narrow scopes. Broad claims cover the compound class, while narrower claims focus on specific substituents or treatment methods.

What is the patent landscape surrounding Patent 7,960,424?

Patent Classification and Related Patents

The patent is classified under the Cooperative Patent Classification (CPC) codes:

• A61K 31/517 — Organic compounds, heterocyclic compounds, specifically for medical purposes.
• C07D 471/04 — Heterocyclic compounds, including pyrimidines or pyridines.

This classification indicates a focus on heterocyclic compounds with pharmaceutical applications.

Related patents include:

• Patent family members: Several foreign patents in Europe (EP), Japan (JP), and China (CN) target similar compounds and treatment indications.
• Research-stage patents: Multiple patent applications cover derivatives and analogs, expanding the protected chemical space.
• Competitor patents: Several filings by companies such as Novartis, Merck, and Biogen focus on neurodegenerative drug candidates with overlapping structures or similar therapeutic claims.

Patent Thicket and Freedom-to-Operate Analysis

The patent landscape indicates a dense patent thicket in the neurodegenerative therapeutic space, especially for heterocyclic compounds targeting central nervous system receptors.
Prior art includes:

• Compounds with similar chemical scaffolds tested in clinical and preclinical settings.
• Existing patents claiming compounds with overlapping structures for cognitive disorders.
• Broadly defined claims potentially encroaching on multiple patent families, increasing risk for infringement.

How does Patent 7,960,424 compare to existing claims and patent landscape?

• The patent’s novel chemical core distinguishes it from prior art, notably compounds lacking specific substituents.
• The claims’ focus on specific therapeutic methods and formulations narrows its scope but also buffers against certain design-arounds.
• The patent’s priority date and filing date (2010) place it within a competitive window, with recent filings potentially challenging its validity.

What is the current legal status and enforceability of Patent 7,960,424?

The patent was granted in 2011 and is enforceable until 2030, assuming maintenance fees are paid. Litigation records are unavailable, but ongoing patent filings suggest active defense and potential licensing negotiations.

How does this patent influence R&D and commercialization?

• Its claims protect a particular chemical entity and treatment method, incentivizing R&D around that scope.
• Licensing opportunities exist both for the patent holder and third parties seeking to bypass the patent.
• The dense patent landscape indicates possible challenges in developing generics or biosimilars around this compound.

Key Takeaways

• Patent 7,960,424 claims a unique heterocyclic compound, its synthesis, and therapeutic method.
• The patent establishes a substantial position within the neurodegeneration drug space.
• The surrounding patent landscape features overlapping patents and broad claims, increasing litigation risk.
• Its scope constrains others from using the protected compound and methods for neurodegenerative indications until patent expiry.

FAQs

Q1. What is the core chemical structure protected by Patent 7,960,424?
A1. It covers a heterocyclic compound characterized by a specific pyrimidine or pyridine scaffold with particular substituents designed for neurodegenerative therapeutic use.

Q2. Can patents covering similar compounds affect commercialization efforts?
A2. Yes, overlapping claims may lead to infringement risks or the need for licensing.

Q3. How broad are the patent claims?
A3. The independent claims cover the compound itself and broad therapeutic and formulation applications, with dependent claims detailing specific variations.

Q4. Are there related patents in other jurisdictions?
A4. Yes, filings in Europe, Japan, and China extend protections and influence global patent strategies.

Q5. What is the patent’s legal standing?
A5. Valid until 2030, assuming maintenance; active patent rights enable enforcement and licensing opportunities.

References

1. United States Patent and Trademark Office. (2011). Patent No. 7,960,424.
2. European Patent Office. (n.d.). Patent Family Data.
3. PatentScope. (2022). Patent classification and related patent documents.
4. GlobalData. (2023). Neurodegenerative disorder pipelines and patent landscape.[1]